<DOC>
	<DOC>NCT02191137</DOC>
	<brief_summary>The MOTION study is a prospective, Phase IV study, enrolling 61 patients with Pulmonary Arterial Hypertension (PAH). The study designed to further explore patient-reported outcomes in PAH subjects who are not on active treatment and living in the United States. In addition, the study will be exploring the use of new telemetric technology (Accelerator band) to evaluate if this technology correlates with improvements in 6 Minute Walking Distance 6MWD in patients with PAH</brief_summary>
	<brief_title>Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Male or female patients, 18 to 80 years of age at Visit 0 Women of childbearing potential must have a negative pretreatment pregnancy test, negative monthly pregnancy test, and must use reliable methods of contraception according to the Risk Evaluation Mitigation Strategies (REMS) guidance Symptomatic pulmonary arterial hypertension, World Health Organization Group 1 with a pulmonary vascular resistance (PVR) &gt;300 dyn*sec*cm5, mean pulmonary artery pressure (PAP mean) ≥25 mmHg, and pulmonary capillary wedge pressure (PCWP) ≤15 mmHg as assessed by right heart catheterization within 6 months prior to Screening (Visit 0) PAH of the following types: Idiopathic (IPAH) Familial (FPAH) Associated with PAH (APAH) due to: Connective tissue disease Congenital heart disease, but only if patient underwent surgical repair more than one year before enrollment Anorexigen or amphetamine use Portal hypertension with liver cirrhosis Not treated with PAHspecific pulmonary medications within 14 days of Screening (Visit 0) 6MWD between 150 meters and 450 meters Patients who are pregnant Patients currently on nitrate and/or nitric oxide (NO) donor therapy; patients currently taking phosphodiesterase 5 (PDE5) inhibitors (such as sildenafil, tadalafil, vardenafil) and nonspecific PDE inhibitors (theophylline, dipyridamole) NonWHO group 1 Pulmonary Hypertension Severe restrictive lung disease History of uncontrolled high blood pressure or hypotension A medical disorder, condition, or history that in the opinion of the Investigator would impair their ability to participate or complete this study Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Hypertension,Riociguat,Living with Pulmonary Hypertension Questionnaire</keyword>
</DOC>